While the mean reduction by anti–IL-1β was comparatively small, it is interesting to note that a small subset of RA and gout synovial fluids showed stronger decreases of CXCL1/5 secretion upon anti–IL-1β treatment (Supplemental Figure 5B). This evidence concerns the gene CXCL1 and gout.